ABCL
USDAbCellera Biologics Inc. Common Shares
Reaalajas hind
Hinnagraafik
Põhinäitajad
Turunäitajad
Avatud
$3.200
Kõrge
$3.310
Madal
$3.080
Maht
8.00M
Ettevõtte fundamentaalnäitajad
Turukapitalisatsioon
940.2M
Tööstusharu
Biotehnoloogia
Riik
Canada
Kauplemisstatistika
Keskmine maht
4.49M
Börs
NMS
Valuuta
USD
52 nädala vahemik
Seotud uudised
Truist Securities Maintains Buy on AbCellera Biologics, Lowers Price Target to $10
Truist Securities analyst Robyn Karnauskas maintains AbCellera Biologics with a Buy and lowers the price target from $28 to $10.
AbCellera Receives Authorization from Health Canada to Initiate the Phase 1 Clinical Trial of ABCL635 for Vasomotor Symptoms Due to Menopause
AbCellera anticipates starting the Phase 1 clinical trial for ABCL635 in Q3 2025 AbCellera (NASDAQ:ABCL) today announced it has received a No Objection Letter (NOL) from Health Canada authorizing its Clinical Trial
AbCellera Reports Q1 2025 Business Results
AbCellera (NASDAQ:ABCL) today announced financial results for the first quarter of 2025. All financial information in this press release is reported in U.S. dollars, unless otherwise indicated. "After completion of a
AbCellera Presents Data Showing Preclinical Efficacy of PSMA x CD3 T-Cell Engagers at AACR 2025
Preclinical data on AbCellera's PSMA x CD3 T-cell engagers demonstrate potent anti-tumor activity and potential to further enhance function through costimulatory strategies AbCellera (NASDAQ:ABCL) today announced new
Seotud aktsiad
Püsi kursis
Määrake hinnateavitused, hankige tehisintellekti analüüsi uuendusi ja reaalajas turuuudiseid.